Assessment of health-related quality of life (HRQoL) in patients with spasmodic dysphonia
DOI:
https://doi.org/10.18203/2349-3933.ijam20182392Keywords:
BDI, HRQoL, SD, SF-36, VPQ, VoiSSAbstract
Background: There is paucity of literature regarding health related quality of life in Spasmodic Dysphonia (SD) especially from India. This study assessed HRQoL in it’s global and disease specific aspect by previously validated instruments in patients with SD.
Methods: The study was performed in AIIMS, New Delhi. Subjects with SD as well as age and gender matched healthy controls were enrolled from Movement Disorder and botulinum toxin clinic, Department of Neurology, AIIMS, New Delhi. Uneducated patient, those could not read questionnaires & cases who had received botulinum toxin within 6 months were excluded from the study. Each patient filled SF-36, BDI, VoiSS-30 and VPQ questionnaire.
Results: 14 pts of Spasmodic Dysphonia (SD) were enrolled. Compared with controls SD patients suffered from statistically significant impaired global health related quality of life (SF36) in areas of role physical (p = 0.007), general health (p = 0.004), social functioning (p = 0.024), role emotion (p = 0.008) and mental health (p=0.039). Patients with SD scored much worse in BDI scale than their control group (12.57±8.0 vs. 4.71±5.0, p=0.005). 65% pt of SD had depression out of whom 14% had moderate depression. SD patient group showed statistically significant impaired scores in disease-specific QOL (VoISS) in 2 out of 3 subscales, impairment (p= <0.001) and emotional (p=<.001) but not in physical (p=0.44). Voice quality of patients with SD was severely affected compared to controls (mean 37± 8.0 vs. 12.9± 1.5).
Conclusions: This study clearly demonstrated that patients with SD suffered from significant impairment in HRQoL as compared to controls. Higher proportion of patients with SD suffered from mild to moderate depression compared to their control.
References
Jankovic J, Tolosa E. Parkinson’s Disease and Movement Disorders: 5th edition, 2007edited by Jankovic, J: 321-347.
Nutt JG, Muenter MD, Aronson A. Epidemiology of focal and generalized dystonias in Rochester, Minnesota. Mov Dis 1988;3(3):188-94
Khanh D L, Beate N. The prevalence of primary dystonia in general community. Neurology. 2003;61:1294-6.
The ESDE Collaborative group. A prevalence study of primary dystonia in eight European countries. J Neurol. 2000;247(10):77-92.
Das SK, Tapas KB. Community survey of primary dystonia in the city of Kolkata, India. Movement Disorders. 2007;22(14): 2031-36.
Revicki DA, Osoba D, Fairclough D, Barofsky I, Berzon R, Leidy NK, et al. Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Quality Life Res. 2000;9(8):887-900
Ware JE, Jr, Kosinski M, Gandek. The factor structure of the SF-36 health survey in 10 countries: result from the IQOLA Project. International Study of Life Assessment. J Clin Epidemiol 1998;51:1159-65
Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 Jun;30(6):473-83.
Deary IJ, Wilson JA, Carding PN, MacKenzie K. VoiSS: a patient-derived voice symptom scale. J Psychosom Res. 2003;54(5):483-9.
Wilson JA, Webb A, Carding PN, Steen IN, MacKenzie K, Deary IJ. The Voice Symptom Scale (VoiSS) and the Vocal Handicap Index (VHI): a comparison of structure and content. Clin Otolaryngol. 2004;29(2):169-74.
Deary IJ, Webb A, Mackenzie K, Wilson JA, Carding PN. Short, self-report voice symptom scales: psychometric characteristics of the voice handicap index-10 and the vocal performance questionnaire. Otolaryngol Head Neck Surg. 2004;131(3):232-5.
Costa J, Espirito-Santo C, Borges A, Ferreira JJ Botulinum toxin type A therapy for blepharospasm (Review) The Cochrane Library, 2004.
Costa J, Espírito‐Santo CC, Borges AA, Ferreira J, Coelho MM, Moore P, Sampaio C. Botulinum toxin type A therapy for hemifacial spasm. The Cochrane Library. 2005.
Singh SK, Yadav A, Mokamati S, Galagali JR, Kanzhuly MK, Kumar N, et al. A study of voice changes in spasmodic dysphonia after botulinum therapy. J Evolution Med Dent Sci. 2016;5(22):1152-5.
Gündel H, Busch R, Ceballos‐Baumann A, Seifert E. A Psychiatric co morbidity in patients with spasmodic dysphonia: a controlled study. J Neurol Neurosurg Psychiatry. 2007;78(12):1398-1400.
Liu CY, Yu JM, Wang NM, Chen RS, Chang HC, Li HY, et al. Emotional symptoms are secondary to the voice disorder in patients with spasmodic dysphonia. Gen Hosp Psych. 1998;20(4):255-9
Courey MS, Garrett CG, Portell MD, Billante CR, Smith TL, Stone RE, et al. Outcomes assessment following treatment of spasmodic dysphonia with botulinum toxin. Annal Otol Rhinol Laryngol. 2000;109(9):819-22.
Smith E, Taylor M, Mendoza M, Barkmeier J, Lemke J, Hoffman H. Spasmodic dysphonia and vocal fold paralysis: outcomes of voice problems on work-related functioning. J Voice. 1998;12(2):223-32.
Benninger MS, Gardner G, Grywalski C. Outcomes of botulinum toxin treatment for patients with spasmodic dysphonia. Arch Otolaryngol Head Neck Surg. 2001;127(9):1083-85.
Paniello RC, Barlow J, Serna JS. Longitudinal Follow‐Up of Adductor Spasmodic Dysphonia Patients After Botulinum Toxin Injection: Quality of Life Results. Laryngoscope. 2008;118(3):564-8
Jones SM, Carding PN, Drinnan MJ. Exploring the relationship between severity of dysphonia and voice-related quality of life. Clin Otolaryngol. 2006;31(5):411-17.
Bhattacharya N, Tarsy D. Impact on quality of life of botulinum toxin treatments for spasmodic dysphonia and oromandibular dystonia. Arch Otolaryngol Head Neck Surg. 2001;127(4):389-92.
Baylor CR, Yorkston KM. The consequences of spasmodic dysphonia on communication-related quality of life: A qualitative study of the insider's experiences. J Commun Disord. 2005;38(5):395-419.
Watts CR, Truong DD, Nye C. Evidence for the effectiveness of botulinum toxin for spasmodic dysphonia from high-quality research designs. J Neural Transm (Vienna). 2008;115(4):625-30.
